CRISPR Therapeutics (NasdaqGM:CRSP) witnessed a notable 25% gain over the past week, gaining traction amid an executive departure. The announcement of COO Julianne Bruno’s exit could have influenced ...

Phase Ib results show VERVE-102 reduced LDL-C levels with no serious safety issues, unlike Verve’s VERVE-101 programme.

From STAT’s Matthew Herper: Pfizer said this morning that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity, focusing its efforts on another medicine with ...

Verve Therapeutics said Monday that initial data show that its investigational gene-editing therapy lowered cholesterol without inducing serious side effects.

Vertex Pharmaceuticals (NASDAQ: VRTX) is a great example of biotech success. It recently won approval for a non-opioid pain ...

A revolution is underway in gene editing -- and at its forefront is David Liu, an American molecular biologist whose ...

CRISPR Therapeutics (NasdaqGM:CRSP) experienced an 12% price decline over the last week, coinciding with significant market disruption driven by escalating tariff tensions, which saw the S&P 500 and ...

Donald Trump Tariff Announcement Highlights: US President Donald Trump has unveiled a comprehensive tariff policy, imposing at least a 10% duty on nearly all goods entering the United States.

The decline in biotech stocks comes after FDA official Peter Marks' resignation, citing irreconcilable differences with the new HHS Secretary.

Following the above announcement, vaccine makers were ... of Sarepta Therapeutics SRPT lost more than 9% while those of CRISPR Therapeutics CRSP declined 8%. Both companies have an FDA-approved ...